Targeted therapy directed by genetic testing in treating patients with advanced solid tumors, lymphomas, or multiple myeloma
Will identifying genetic abnormalities in tumor cells help doctors plan better, more personalized treatment for cancer patients?
a study on Malignant Solid Neoplasm Bladder Cancer Breast Cancer Cervical Cancer Colon Cancer Colorectal Cancer Endometrial Cancer Esophageal Cancer Stomach Cancer Glioma Head and Neck Cancer Kidney Cancer Cholangiocarcinoma Lung Cancer Lymphoma Malignant Uterine Neoplasm Skin Cancer/Melanoma Multiple Myeloma Ovarian Cancer Pancreatic Cancer Prostate Cancer Rectal Cancer Liver Cancer Thyroid Cancer Uterine Cancer Refractory Malignant Solid Neoplasm Solid Tumor Carcinoma Neoplasms Lung Tumor Colorectal Tumor Ovarian Epithelial Carcinoma Pancreatic Neoplasms Urinary Bladder Tumor Hepatocellular Carcinoma Renal Cell Carcinoma Kidney Neoplasm Hepatocellular Cancer
- for people ages 18 years and up (full criteria)
- at UC Davis UC Irvine UCSD
- study startedestimated completion
Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Kidney Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Recurrent Uterine Corpus Cancer, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma, Uterine Corpus Cancer, Carcinoma, Neoplasms, Plasma Cell Neoplasms, Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms, Ovarian Epithelial Carcinoma, Prostatic Neoplasms, Pancreatic Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Urinary Bladder Neoplasms, Rectal Neoplasms, Colonic Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Hepatocellular Carcinoma, Skin Neoplasms, Renal Cell Carcinoma, Kidney Neoplasms, Thyroid Diseases, Recurrence, Nivolumab, Trastuzumab, Pertuzumab, Ado-Trastuzumab Emtansine, Relatlimab, Sunitinib, Dasatinib, Palbociclib, Trametinib, Osimertinib, Afatinib, Dabrafenib, Crizotinib, Maytansine, Ipatasertib, Trastuzumab biosimilar HLX02, GSK2636771, Antibodies, Immunoglobulins, Immunoglobulin G, Adavosertib, Tyrosine Protein Kinase Inhibitors, Immunoconjugates, Afatinib Dimaleate, Binimetinib, Biopsy, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Cytology Specimen Collection Procedure, Dabrafenib Mesylate, Defactinib, Defactinib Hydrochloride, Erdafitinib, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, PI3K-beta Inhibitor GSK2636771, Sapanisertib, Sunitinib Malate, Taselisib, Trastuzumab Emtansine, Ulixertinib, Vismodegib, EGFR activating mutation, HER2 activating mutation, MET amplification, MET exon 14 deletion/mutation, ALK translocation, BRAF V600E/R/K/D mutation, PIK3CA mutation, HER2 amplification >= 7 copy numbers, FGFR amplification, mTOR mutation